Could a common arthritis pill fight brain diseases?
NCT ID NCT05189106
Summary
This early-stage study tested whether baricitinib, a drug approved for rheumatoid arthritis, can get into the spinal fluid and reduce signs of brain inflammation in people with Alzheimer's disease, ALS, or early memory concerns. Seventeen participants took the pill daily for 24 weeks. The main goal was to measure drug levels and inflammatory markers in spinal fluid, not to see if it improved symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital - AD Site
Charlestown, Massachusetts, 02129, United States
-
Massachusetts General Hospital - ALS Site
Boston, Massachusetts, 02129, United States
Conditions
Explore the condition pages connected to this study.